Meeting Regulatory Requirements for Drugs with a Narrow Therapeutic Index: Bioequivalence Studies of Generic Once-Daily Tacrolimus

• Published in: Drug, healthcare and patient safety healthcare and patient safety, 2020-01, Vol.12, p.151-160
• Main Authors: Gantar, Kaja, Škerget, Katja, Mochkin, Ilya, Bajc, Aleksander
• Format: Article
• Language: English
• Subjects: Bioequivalence; Cost control; Drug approval; FDA approval; generic; Generic drugs; Health aspects; Health care costs; Kidney transplants; Laws, regulations and rules; Liver; narrow therapeutic index; once-daily; Organ transplantation; Patients; Physicians; Prescription drugs; Regulatory approval; Regulatory compliance; Tacrolimus
• ISSN: 1179-1365; 1179-1365
• DOI: 10.2147/DHPS.S256455

Despite growing clinical confidence in generics and their potential to reduce long-term healthcare costs, the transplant community have had real concerns about the use of generic immunosuppressants. One such immunosuppressant is tacrolimus, a cornerstone of lifelong treatment for patients who have undergone a solid organ transplant. Tacrolimus has a narrow therapeutic index (NTI), giving rise to questions about the potential for clinically relevant altered drug exposure. Its use in transplant patients also gives rise to questions about the most discriminative subject population for bioequivalence studies. The recognised need for stringent criteria to support approval of generic drugs with an NTI led the European Medicines Association and Health Canada to provide detailed information on requirements for bioequivalence studies and introduce tighter bioequivalence limits for these drugs, including tacrolimus. The aim of this article is to illustrate how regulatory guidance is implemented during the clinical development of generic immunosuppressants, using a generic, once-daily prolonged-release formulation of tacrolimus as an example.